Tanmay Sahai, MD
Medical Oncology · Urbana, ILNPI 1104265347
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 59.0% of the total. 2025 is the largest year on record at $1,624, 2.5 times the $640 reported in 2019.
Across 37 payments — averaging $82.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- AbbVie$271
- AstraZeneca$195
- Amgen$175
- GSK$156
- Lilly USA, LLC$106
- plus $345 from 10 others
Across 45 payments — averaging $5670.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biontech SE$255K
What the payments were for
- Consulting fees$1,57552%
- Food & beverage$90130%
- Education$56819%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $1,796 |
| AbbVie | 6 | $271 |
| AstraZeneca(2 entities) | 3 | $195 |
| Amgen | 2 | $175 |
| GSK | 3 | $156 |
| Lilly USA, LLC | 1 | $106 |
| Novartis | 4 | $71 |
| Astellas Pharma US Inc | 2 | $48 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Eisai Inc. | 2 | $35 |
| Bristol Myers Squibb | 2 | $34 |
| Pfizer | 2 | $33 |
| Merck | 2 | $32 |
| Incyte Corporation | 1 | $23 |
| ADC Therapeutics America, Inc. | 1 | $19 |
| Taiho Oncology, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,043 in reported general payments places this provider in the 60th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 17 | $298,572 |
| JaypircaPirtobrutinib | 11 | $247,398 |
| Lenalidomide | 13 | $192,457 |
| ErleadaApalutamide | 12 | $183,235 |
| EliquisApixaban | 56 | $51,490 |
| XareltoRivaroxaban | 50 | $29,023 |
| Abiraterone Acetate | 16 | $28,964 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $954 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $825 |
| Acyclovir | 26 | $598 |
| Ondansetron OdtOndansetron | 59 | $531 |
| Dexamethasone | 41 | $496 |
| Prochlorperazine Maleate | 53 | $479 |
| Warfarin Sodium | 15 | $300 |
| Hydroxyurea | 27 | $277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $34 | $298,57217 claims |
| Lilly USA, LLCJaypirca, Olanzapine | $106 | $247,58840 claims |
| PfizerEliquis | $33 | $51,49056 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 144 medical oncology providers in Illinois.
Other medical oncology in Urbana
- Vamsi VasireddyUrbana$3K
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Timothy KuzelOrland Park$265K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
- Nicklas PfanzelterGlenview$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.